Loading…
NanoViricides, Inc. is projected to rise to $1.99 by 2027, a +24% move from its current price of $1.61. NNVC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.53 | $1.61 | $1.69 | -0.06% |
| Jul 14 | $1.50 | $1.61 | $1.72 | -0.13% |
| Jul 15 | $1.48 | $1.61 | $1.75 | -0.19% |
| Jul 16 | $1.46 | $1.61 | $1.77 | -0.25% |
| Jul 17 | $1.44 | $1.60 | $1.79 | -0.31% |
| Jul 18 | $1.42 | $1.60 | $1.81 | -0.38% |
| Jul 19 | $1.41 | $1.60 | $1.82 | -0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.41 | $1.60 | $1.82 | -0.44% |
| Week 2 | $1.33 | $1.60 | $1.92 | -0.88% |
| Week 3 | $1.27 | $1.59 | $1.99 | -1.31% |
| Week 4 | $1.22 | $1.58 | $2.05 | -1.75% |
| Week 5 | $1.18 | $1.57 | $2.10 | -2.18% |
| Week 6 | $1.14 | $1.57 | $2.15 | -2.61% |
| Week 7 | $1.11 | $1.56 | $2.20 | -3.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NanoViricides, Inc. is a clinical stage nano-biopharmaceutical company focused on discovering, developing, and commercializing drugs to combat viral infections. The description identifies its product portfolio and confirms work on NV-387 for RSV and influenza, with completed phase 1a/1b human clinical trials for safety and tolerability.
NV-387 is described as an active ingredient in drug product formulations for COVID infections, including NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies that are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration for pediatric treatments. The company also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized, plus an injectable solution delivered as a lung fog via nebulizer devices to target respiratory viruses.
The description also covers NV-HHV-1, a skin cream for Shingles rash, plus an oral drug with NV-HHV-1 for HSV-1 and HSV-2, along with other drug candidates in an HIVCide program for Dengue and Ebola virus, and the Nanoviricide platform technology. NanoViricides was incorporated in 2005 and is headquartered in Shelton, Connecticut.
NNVC is the equity name for NanoViricides, Inc., which currently trades with a price of $1.61 and has a market cap of $37M, ranking 4702 by market capitalization. The asset’s longitudinal forecast shows the 2026 average price at $1.61, with higher potential in subsequent years, culminating in a 2050 average of $21.66 and a max forecast of $49.82. The projected ranges imply meaningful upside over the long horizon, with a wide spread between min and max prices in later years.
A major floor 46.0% below — a decisive break under it would weaken the trend.
The nearest floor, 24.2% below — buyers have tended to step in here.
The nearest ceiling, 15.5% above — a clean break opens room to run.
A major ceiling 34.8% above — clearing it would confirm fresh momentum.
Key NNVC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NNVC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.53 | Buy | $1.51 | Buy |
| MA 10 | $1.44 | Buy | $1.47 | Buy |
| MA 20 | $1.39 | Buy | $1.44 | Buy |
| MA 50 | $1.47 | Buy | $1.41 | Buy |
| MA 100 | $1.27 | Buy | $1.34 | Buy |
| MA 200 | $1.29 | Buy | $1.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.35 | Neutral |
| Stoch RSI (14) | 60.96 | Neutral |
| CCI (20) | 111.11 | Buy |
| Williams %R (14) | -32.26 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 15.27 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 67.74 | Neutral |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 58.56 | Neutral |
| Momentum (10) | 0.21 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 1.60 | Buy |
| ADX (14) | 11.63 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is labeled BULLISH, with RSI(14) at 60. The stock’s near-term moving averages show a SMA50 of $1.46 and a SMA200 of $1.29, framing a constructive trend. Support is cited at $1.22 and resistance at $1.86, guiding short-term price action.
The 30-day price range runs from a low of $1.17 to a high of $2.22, underscoring a broad trading band. Annualized volatility is high, listed at 90%, indicating substantial price swing potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.85 | $1.61 | $2.15 | 0% | Neutral | |
| $1.47 | $1.99 | $2.91 | +24% | Bullish | |
| $1.52 | $2.18 | $3.38 | +35% | Bullish | |
| $1.27 | $1.90 | $3.09 | +18% | Neutral | |
| $1.74 | $2.72 | $4.59 | +69% | Bullish | |
| $2.38 | $3.87 | $6.73 | +140% | Bullish | |
| $2.50 | $4.22 | $7.56 | +162% | Bullish | |
| $2.79 | $4.87 | $8.96 | +202% | Bullish | |
| $2.59 | $4.69 | $8.83 | +191% | Bullish | |
| $2.56 | $4.78 | $9.20 | +197% | Bullish | |
| $3.95 | $8.67 | $18.26 | +438% | Bullish | |
| $9.65 | $21.45 | $49.33 | +12.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.85 | $1.61 | $1.96 | +0.00% |
| August 2026 | $1.26 | $1.52 | $1.90 | -5.62% |
| September 2026 | $1.24 | $1.52 | $1.94 | +0.05% |
| October 2026 | $1.30 | $1.61 | $2.09 | +5.93% |
| November 2026 | $1.30 | $1.62 | $2.13 | +0.58% |
| December 2026 | $1.29 | $1.62 | $2.15 | -0.18% |
Click any year to see its month-by-month NNVC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NanoViricides, Inc.'s 2026 outlook centres on $1.61, within a $0.85 to $2.15 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NNVC could reach as high as $2.91, with a base case around $1.99 and support toward $1.47 — roughly +24% from $1.61. Buyers look set to stay in control over this stretch.
Expect NNVC to range from $1.52 to $3.38 through 2028. The $2.18 average target implies a +35% move from current prices. That is up +9% on the projected 2027 average. Momentum favours further upside here.
The NNVC price prediction for 2029 points to an average of $1.90 (low $1.27, high $3.09) — a potential gain of +18% on today's $1.61. A consolidation phase looks the most probable path here.
In 2030, NNVC is projected to trade between $1.74 and $4.59, averaging $2.72 — a potential gain of +69% from today's $1.61. That is up +43% on the projected 2029 average. Momentum favours further upside here.
NanoViricides, Inc.'s 2031 outlook centres on $3.87, within a $2.38 to $6.73 range. That is up +42% on the projected 2030 average. That marks a +140% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NNVC could reach as high as $7.56, with a base case around $4.22 and support toward $2.50 — roughly +162% from $1.61. Momentum favours further upside here.
Expect NNVC to range from $2.79 to $8.96 through 2033. The $4.87 average target implies a +202% move from current prices. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NNVC price prediction for 2034 points to an average of $4.69 (low $2.59, high $8.83) — a potential gain of +191% on today's $1.61. Momentum favours further upside here.
In 2035, NNVC is projected to trade between $2.56 and $9.20, averaging $4.78 — a potential gain of +197% from today's $1.61. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
NanoViricides, Inc.'s 2040 outlook centres on $8.67, within a $3.95 to $18.26 range. That is up +82% on the projected 2035 average. That marks a +438% change versus current levels. Momentum favours further upside here.
By 2050, NNVC could reach as high as $49.33, with a base case around $21.45 and support toward $9.65 — roughly +12.3x from $1.61. Buyers look set to stay in control over this stretch.
Investing $1,000 in NNVC today (≈ 621.118012 NNVC) could be worth
$13,322.71
+$12,322.71 (+1232%) by 2050 · US Dollar
Based on the average projected NNVC price of $21.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NNVCwould be worth at today's price.
$1,000 invested in NNVC on Jul 10, 2025 (≈ 709.219875 NNVC) would be worth
$1,141.84
+$141.84 (+14.2%) today · 1.14× · US Dollar
Based on a NNVC entry price of $1.41 vs. today's $1.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.33 | $1,210.53 | +21.1% |
| 1 month ago | $1.34 | $1,201.49 | +20.1% |
| 3 months ago | $0.98 | $1,642.86 | +64.3% |
| 6 months ago | $1.13 | $1,424.78 | +42.5% |
| 1 year ago | $1.41 | $1,141.84 | +14.2% |
| All time (5.0y) ago | $4 | $402.5 | -59.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NNVC forecast.
Our base-case forecast reaches $3.20 around 2031.
Implied market cap at $3.20: $73.55M
The multi-year forecast presents a clear ascent from 2026 onward. The 2026 average is $1.61 with a min of $0.85 and a max of $2.16, and a 0% ROI, with a NEUTRAL sentiment. By 2027 the average rises to $2.00 (min $1.48, max $2.92) and a 24.1% ROI with a BULLISH sentiment.
The 2028 forecast shows an average of $2.18 (min $1.52, max $3.37) and a 35.3% ROI, still bullish, followed by 2029’s average of $1.91 (min $1.28, max $3.10) with an 18.7% ROI and NEUTRAL sentiment.
Looking further ahead, 2030 is modeled at an average of $2.74 (min $1.76, max $4.62) with a 70.3% ROI and BULLISH sentiment. 2031 through 2035 continue the bullish arc with average prices of $3.88, $4.24, $4.90, $4.71, and $4.81 respectively, and ROIs of 141.1%, 163.1%, 204.2%, 192.7%, and 198.7%. By 2040 the forecast jumps to an average of $8.71 (min $3.99, max $18.29) with a 440.9% ROI and a BULLISH stance.
In 2050 the average is projected at $21.66 (min $9.75, max $49.82) representing a 1245.5% ROI, with bullish sentiment.
These are estimates, not guarantees, and actual results will depend on market conditions and company developments. The long-horizon outlook shows substantial upside potential in the later years, but also notable uncertainty and risk in early periods.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.74, with a min of $1.76 and a max of $4.62, and a 70.3% ROI. The sentiment is BULLISH.
Forecasts indicate a bullish trend from 2027 onward, with progressively higher average prices and ROIs through 2050, though 2026 shows a neutral stance and 2029 remains mixed. These are estimates, not guarantees.
Yes, the long-horizon max forecasts extend above $10, with 2040 max at $18.29 and 2050 max at $49.82, though these represent potential upside ranges rather than a guaranteed path.
Market cap is $37M and it ranks 4702.
NanoViricides, Inc. Community Discussion
0Share your NanoViricides, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.